for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Clovis Oncology Inc

CLVS.O

Latest Trade

6.68USD

Change

0.00(0.00%)

Volume

998

Today's Range

--

 - 

--

52 Week Range

3.62

 - 

11.63

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
6.68
Open
0.00
Volume
998
3M AVG Volume
106.06
Today's High
--
Today's Low
--
52 Week High
11.63
52 Week Low
3.62
Shares Out (MIL)
88.32
Market Cap (MIL)
589.97
Forward P/E
-1.67
Dividend (Yield %)
--

Next Event

Q4 2020 Clovis Oncology Inc Earnings Release

Latest Developments

More

Clovis Oncology Announces Preliminary Product Revenues For Q4 And Full Year 2020

Clovis Oncology's Rubraca Met The Primary Endpoint In Phase 3 Treatment Study In Later-Line Ovarian Cancer Patients With A Brca Mutation

Clovis Oncology Reports Q3 Loss Per Share $0.89

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Clovis Oncology Inc

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product Rubraca (rucaparib), an oral small molecule inhibitor of poly adenosine diphosphate (ADP)-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The Company also provides Lucitanib, which is an investigational, oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors one through three (VEGFR1-3), platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors one through three (FGFR1-3).

Industry

Biotechnology & Drugs

Contact Info

5500 Flatiron Pkwy Unit 100

BOULDER, CO

80301-2834

United States

+1.303.6255000

http://clovisoncology.com

Executive Leadership

Ginger L. Graham

Independent Chairman of the Board

Patrick J. Mahaffy

President, Chief Executive Officer, Co-Founder, Director

Gillian C. Ivers-Read

Co-Founder, Executive Vice President, Chief Regulatory Officer

Daniel W. Muehl

Chief Financial Officer, Executive Vice President

Paul E. Gross

Executive Vice President, General Counsel

Key Stats

3.33 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.1K

2018

0.1K

2019

0.1K

2020(E)

0.2K
EPS (USD)

2017

-7.360

2018

-7.070

2019

-7.430

2020(E)

-4.020
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.68
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-68.82
Return on Equity (TTM)
-56.45

Latest News

Latest News

BRIEF-Clovis Oncology To Highlight Rubraca And Lucitanib Non-Clinical Data At The AACR Virtual Annual Meeting II 2020

* CLOVIS ONCOLOGY TO HIGHLIGHT RUBRACA® (RUCAPARIB) AND LUCITANIB NON-CLINICAL DATA AT THE AACR VIRTUAL ANNUAL MEETING II 2020 Source text for Eikon: Further company coverage:

BRIEF-Clovis Oncology Announces Completion Of Target Enrollment In The Athena Trial, A Phase 3 Maintenance Treatment Study In Front-Line, Newly-Diagnosed Advanced Ovarian Cancer

* CLOVIS ONCOLOGY ANNOUNCES COMPLETION OF TARGET ENROLLMENT IN THE ATHENA TRIAL, A PHASE 3 MAINTENANCE TREATMENT STUDY IN FRONT-LINE, NEWLY-DIAGNOSED ADVANCED OVARIAN CANCER

BRIEF-Clovis Oncology Announces New Recommendations For Rubraca For Treatment Of Metastatic Castration-Resistant Prostate Cancer

* CLOVIS ONCOLOGY - ANNOUNCES NEW RECOMMENDATIONS FOR RUBRACA FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER Source text for Eikon: Further company coverage:

BRIEF-Clovis Oncology Announces Pricing Of Public Offering Of Common Stock

* CLOVIS ONCOLOGY ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Clovis Oncology Announces Proposed Offering Of Common Stock

* CLOVIS ONCOLOGY ANNOUNCES PROPOSED OFFERING OF COMMON STOCK

BRIEF-Clovis Oncology Says Price For Rubraca In Prostate Cancer Will Align To Pricing For Ovarian Cancer Indications

* CLOVIS ONCOLOGY - PRICE FOR RUBRACA IN PROSTATE CANCER WILL ALIGN TO PRICING FOR OVARIAN CANCER INDICATIONS

Clovis Oncology's Rubraca gets FDA approval for prostate cancer

Clovis Oncology Inc said on Friday the U.S. Food and Drug Administration has approved its drug Rubraca for the treatment of adult patients with metastatic castration-resistant prostate cancer, whose tumors have a genetic mutation.

Clovis Oncology's Rubraca gets U.S. FDA approval for prostate cancer

Clovis Oncology Inc said on Friday the U.S. Food and Drug Administration has approved its drug Rubraca for the treatment of adult patients with castration-resistant prostate cancer, whose tumors have a genetic mutation. The approval is for the drug's use in patients whose...

BRIEF-FDA Approves Clovis Oncology's Rubraca For Certain Prostate Cancer Patients

* RUBRACA® (RUCAPARIB) APPROVED IN THE U.S. AS MONOTHERAPY TREATMENT FOR PATIENTS WITH BRCA1/2-MUTANT, METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) WHO HAVE BEEN TREATED WITH ANDROGEN RECEPTOR-DIRECTED THERAPY AND A TAXANE-BASED CHEMOTHERAPY

BRIEF-Clovis Oncology Announces First Quarter 2020 Operating Results

* CLOVIS ONCOLOGY ANNOUNCES FIRST QUARTER 2020 OPERATING RESULTS

BRIEF-Clovis Oncology Says CEO Patrick J. Mahaffy's 2019 Total Compensation Was $6.9 Million

* CLOVIS ONCOLOGY SAYS CEO PATRICK J. MAHAFFY'S 2019 TOTAL COMPENSATION WAS $6.9 MILLION VERSUS $6.3 MILLION IN 2018 – SEC FILING

BRIEF-Clovis Oncology Announces Debt Exchange Transaction

* CLOVIS ONCOLOGY ANNOUNCES DEBT EXCHANGE TRANSACTION Source text for Eikon: Further company coverage:

BRIEF-Clovis Oncology Reports Q4 Loss Per Share $1.81

* Q4 EARNINGS PER SHARE ESTIMATE $-1.71 -- REFINITIV IBES DATA

Clovis Oncology halts mid-stage bladder cancer trial, shares drop

Clovis Oncology Inc said on Friday it was halting a mid-stage trial testing its lead drug in bladder cancer patients, sending shares down 12 percent.

Clovis Oncology, execs to pay $20 million to settle SEC charges

U.S. biotechnology company Clovis Oncology Inc and its Chief Executive Patrick Mahaffy and former CFO Erle Mast, will pay more than $20 million to settle charges of misleading investors about the efficacy of a cancer drug, the top U.S. securities regulator said on Tuesday.

BRIEF-Clovis Oncology Reports Q1 Loss Per Share $1.54

* CLOVIS ONCOLOGY ANNOUNCES FIRST QUARTER 2018 OPERATING RESULTS

BRIEF-Clovis Oncology CEO Patrick Mahaffy's 2017 Total Compensation Was $8.7 Million

* CLOVIS ONCOLOGY INC SAYS CEO PATRICK MAHAFFY'S 2017 TOTAL COMPENSATION WAS $8.7 MILLION – SEC FILING Source text for Eikon: (http://bit.ly/2KnbE4y) Further company coverage:

BRIEF-Clovis Oncology Announces Pricing Of Public Offerings Of Convertible Senior Notes And Common Stock

* CLOVIS ONCOLOGY ANNOUNCES PRICING OF PUBLIC OFFERINGS OF CONVERTIBLE SENIOR NOTES AND COMMON STOCK

BRIEF-Clovis Oncology Files Prospectus Supplement Related To Offering $200 Mln Principal Amount Of Convertible Senior Notes

* CLOVIS ONCOLOGY INC FILES PROSPECTUS SUPPLEMENT RELATED TO OFFERING $200 MILLION PRINCIPAL AMOUNT OF CONVERTIBLE SENIOR NOTES DUE 2025 - SEC FILING Source text: (https://bit.ly/2qzin28) Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Clovis Oncology Files Prospectus Supplement Related To Offering $100 Mln Of Shares Of Co's Common Stock

* CLOVIS ONCOLOGY INC FILES PROSPECTUS SUPPLEMENT RELATED TO OFFERING $100 MILLION OF SHARES OF CO'S COMMON STOCK - SEC FILING Source text: (https://bit.ly/2HCYkbd) Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up